Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
Ardelyx (Nasdaq: ARDX) has launched the Derek Forfang Patient Advocate Award to honor passionate supporters of chronic kidney disease (CKD) patients. The award, named after the late Derek Forfang, aims to recognize individuals who raise awareness of CKD challenges and advocate for the community.
Nominations are open until January 31, 2025, and can be submitted by anyone in the community. Recipients will receive a $1,000 honorarium and a $4,000 donation to a non-profit supporting the CKD community. Eligible nominees must demonstrate achievements in advocating for CKD patients, such as raising awareness, educating others, and advancing research.
The Derek Forfang Patient Advisory Council (DFPAC) will consider candidates for the award. Ardelyx emphasizes the importance of supporting and celebrating voices in the CKD community through this initiative.
Ardelyx (Nasdaq: ARDX) ha lanciato il Premio Derek Forfang per l'Advocacy dei Pazienti per onorare i sostenitori appassionati dei pazienti affetti da malattie renali croniche (MRC). Il premio, intitolato al compianto Derek Forfang, mira a riconoscere coloro che sensibilizzano sulle sfide della MRC e si fanno portavoce della comunità.
Le nomination sono aperte fino al 31 gennaio 2025 e possono essere presentate da chiunque nella comunità. I destinatari riceveranno un onorario di $1.000 e una donazione di $4.000 a un'organizzazione non profit che supporta la comunità MRC. I candidati idonei devono dimostrare risultati nell'advocacy per i pazienti MRC, come la sensibilizzazione, l'educazione al pubblico e la promozione della ricerca.
Il Consiglio Consultivo dei Pazienti Derek Forfang (DFPAC) valuterà i candidati per il premio. Ardelyx sottolinea l'importanza di supportare e celebrare le voci nella comunità MRC attraverso questa iniziativa.
Ardelyx (Nasdaq: ARDX) ha lanzado el Premio Derek Forfang al Defensor del Paciente para honrar a los apasionados defensores de los pacientes con enfermedad renal crónica (ERC). El premio, nombrado en memoria de Derek Forfang, tiene como objetivo reconocer a personas que aumentan la conciencia sobre los desafíos de la ERC y abogan por la comunidad.
Las nominaciones están abiertas hasta el 31 de enero de 2025, y pueden ser presentadas por cualquier persona en la comunidad. Los recipiendarios recibirán un honorario de $1,000 y una donación de $4,000 a una organización sin fines de lucro que apoye a la comunidad de ERC. Los nominados elegibles deben demostrar logros en la defensa de los pacientes de ERC, como aumentar la conciencia, educar a otros y promover la investigación.
El Consejo Asesor de Pacientes Derek Forfang (DFPAC) considerará a los candidatos para el premio. Ardelyx enfatiza la importancia de apoyar y celebrar las voces en la comunidad de ERC a través de esta iniciativa.
Ardelyx (Nasdaq: ARDX)는 만성 신장 질환(CKD) 환자에 대한 열정적인 지지자를 기리기 위해 데렉 포르팡 환자 옹호자상을 시작했습니다. 이 상은 고(故) 데렉 포르팡의 이름을 따서 명명되었으며, CKD의 도전에 대한 인식을 높이고 커뮤니티를 위해 옹호하는 개인을 인정하는 것을 목표로 합니다.
후보 추천은 2025년 1월 31일까지 열려 있으며, 커뮤니티의 누구나 제출할 수 있습니다. 수상자는 1,000달러의 사례비와 CKD 커뮤니티를 지원하는 비영리 단체에 대한 4,000달러의 기부를 받게 됩니다. 자격이 있는 후보자는 CKD 환자를 위한 옹호 활동에서 성과를 보여야 하며, 이에 따라 인식 제고, 타인 교육, 연구 촉진 등이 포함됩니다.
데렉 포르팡 환자 자문 위원회(DFPAC)가 상 후보자를 검토할 예정입니다. Ardelyx는 이 이니셔티브를 통해 CKD 커뮤니티 내 목소리를 지원하고 기념하는 것의 중요성을 강조합니다.
Ardelyx (Nasdaq: ARDX) a lancé le Prix Derek Forfang de l'Advocacy des Patients pour honorer les soutiens passionnés des patients atteints de maladies rénales chroniques (MRC). Le prix, nommé d'après le défunt Derek Forfang, vise à reconnaître les personnes qui sensibilisent aux défis de la MRC et plaident pour la communauté.
Les nominations sont ouvertes jusqu'au 31 janvier 2025 et peuvent être soumises par quiconque dans la communauté. Les lauréats recevront un honorarium de 1 000 $ et une dons de 4 000 $ à une organisation à but non lucratif soutenant la communauté MRC. Les candidats éligibles doivent montrer des réalisations dans la défense des patients MRC, telles que sensibilisation, éducation d'autrui et avancement de la recherche.
Le Conseil Consultatif des Patients Derek Forfang (DFPAC) examinera les candidats pour le prix. Ardelyx souligne l'importance de soutenir et de célébrer les voix de la communauté MRC à travers cette initiative.
Ardelyx (Nasdaq: ARDX) hat den Derek Forfang Patient Advocate Award ins Leben gerufen, um leidenschaftliche Unterstützer von Patienten mit chronischer Nierenerkrankung (CKD) zu ehren. Der Preis, der nach dem verstorbenen Derek Forfang benannt ist, zielt darauf ab, Einzelpersonen zu würdigen, die das Bewusstsein für die Herausforderungen von CKD schärfen und für die Gemeinschaft eintreten.
Nominierungen sind bis zum 31. Januar 2025 möglich und können von jedem in der Gemeinschaft eingereicht werden. Die Preisträger erhalten ein Honorar von 1.000 US-Dollar sowie eine Spende von 4.000 US-Dollar an eine gemeinnützige Organisation, die die CKD-Gemeinschaft unterstützt. Berechtigte Nominierte müssen Erfolge in der Advocacy für CKD-Patienten nachweisen, wie z.B. Sensibilisierung, Aufklärung anderer und Förderung von Forschung.
Der Derek Forfang Patient Advisory Council (DFPAC) wird die Kandidaten für die Auszeichnung prüfen. Ardelyx betont die Bedeutung der Unterstützung und Feier der Stimmen in der CKD-Gemeinschaft durch diese Initiative.
- Ardelyx is actively engaging with the CKD community through the creation of this award
- The initiative may improve Ardelyx's reputation and relationships within the CKD community
- None.
Deadline to submit nominations is January 31, 2025
WALTHAM, Mass., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of the Derek Forfang Patient Advocate Award to recognize passionate supporters of patients living with chronic kidney disease (CKD) who champion the need for innovation and improved health outcomes for patients. This award was established to honor Derek Forfang, an amazing person who suffered from chronic kidney disease and passed away due to issues related to his disease in 2023. Derek was the inspiration and founding member of the Ardelyx Patient Advisory Council, which was just one of the many committees to which Derek belonged. Derek worked tirelessly to improve the lives of patients, families and caregivers in the CKD community. This award serves to recognize individuals who, like Derek, raise awareness of the challenges that kidney patients face, are willing to be the voice for their community and deserve to be recognized for their contributions.
“There are so many individuals, patients, family members and caregivers, who are making incredible efforts to advocate for patients with chronic kidney disease,” said Alan Ryan, DEdMin, Senior Director of Patient Advocacy at Ardelyx. “At Ardelyx, we believe that it is critical to support, celebrate and advance those voices and believe there is no better way to do that than to continue the legacy of our friend and partner, Derek Forfang. There are so many people who are deserving of this recognition, and we encourage everyone in the community to submit a nomination.”
Ardelyx is now accepting nominations for the Derek Forfang Patient Advocate Award. Candidates for the award can be nominated by anyone in the community at large and are considered for the award by the Derek Forfang Patient Advisory Council (DFPAC). To be eligible for the award, nominees must demonstrate achievements and contributions to advocate for CKD patients, which could include raising awareness, educating others, advancing research, advocating for the community and bringing the community together, among many other efforts. Recipients of the Derek Forfang Patient Advocate Award will receive a
Nominations can be submitted online at http://ardelyx.com/DFPAAward. The deadline for nominations is January 31, 2025. Full Terms and Conditions for the award can be found at http://ardelyx.com/DFPAAward.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contact:
Caitlin Lowie
clowie@ardelyx.com
FAQ
What is the Derek Forfang Patient Advocate Award launched by Ardelyx (ARDX)?
When is the deadline for nominations for Ardelyx's (ARDX) Derek Forfang Patient Advocate Award?
What will recipients of Ardelyx's (ARDX) Derek Forfang Patient Advocate Award receive?
Who can nominate candidates for Ardelyx's (ARDX) Derek Forfang Patient Advocate Award?
